IntelliPharmaCeutics And Par Pharmaceutical, Inc. Agree To Controlled Release Generic Drug Development

TORONTO--(BUSINESS WIRE)--Nov. 30, 2005--IntelliPharmaCeutics Corp., a Canadian specialty pharmaceutical company, the operating affiliate of IntelliPharmaCeutics Ltd., (Delaware), is pleased to announce that it has entered into an agreement with Par Pharmaceutical Companies, Inc. (NYSE: PRX) for the development of a generic, controlled release drug product for the United States market.

Back to news